Possible role of the mitochondrial genome in the pathogenesis of autosomal dominant polycystic kidney disease
- PMID: 34331378
- DOI: 10.1111/nep.13957
Possible role of the mitochondrial genome in the pathogenesis of autosomal dominant polycystic kidney disease
Abstract
Autosomal dominant polycystic kidney disease (ADPKD) is the most common monogenic renal disease in adults and is due to heterozygous germ line variants in either PKD1, PKD2 or rarely other genes. It is characterized by marked intra-familial disease variability suggesting that other genetic and/or environmental factors are involved in determining the lifetime course ADPKD. Recently, research indicates that polycystin-mediated mitochondrial dysfunction and metabolic re-programming contributes to the progression of ADPKD. Although biochemical abnormalities have gained the most interest, variants in the mitochondrial genome could be one of the mechanisms underlying the phenotypic variability in ADPKD. This narrative review aims to evaluate the role of the mitochondrial genome in the pathogenesis of APDKD.
Keywords: autosomal dominant polycystic kidney disease; metabolic reprogramming; mitochondrial genome.
© 2021 Asian Pacific Society of Nephrology.
Similar articles
-
Mitochondrial Abnormality Facilitates Cyst Formation in Autosomal Dominant Polycystic Kidney Disease.Mol Cell Biol. 2017 Nov 28;37(24):e00337-17. doi: 10.1128/MCB.00337-17. Print 2017 Dec 15. Mol Cell Biol. 2017. PMID: 28993480 Free PMC article.
-
Metabolic reprogramming in a slowly developing orthologous model of polycystic kidney disease.Am J Physiol Renal Physiol. 2022 Mar 1;322(3):F258-F267. doi: 10.1152/ajprenal.00262.2021. Epub 2022 Jan 17. Am J Physiol Renal Physiol. 2022. PMID: 35037466 Free PMC article.
-
Cilia and polycystic kidney disease.Semin Cell Dev Biol. 2021 Feb;110:139-148. doi: 10.1016/j.semcdb.2020.05.003. Epub 2020 May 28. Semin Cell Dev Biol. 2021. PMID: 32475690 Review.
-
Bilineal inheritance of pathogenic PKD1 and PKD2 variants in a Czech family with autosomal dominant polycystic kidney disease - a case report.BMC Nephrol. 2018 Jul 4;19(1):163. doi: 10.1186/s12882-018-0978-2. BMC Nephrol. 2018. PMID: 29973168 Free PMC article.
-
Molecular pathways and therapies in autosomal-dominant polycystic kidney disease.Physiology (Bethesda). 2015 May;30(3):195-207. doi: 10.1152/physiol.00032.2014. Physiology (Bethesda). 2015. PMID: 25933820 Free PMC article. Review.
Cited by
-
Urinary Biomarkers in Monitoring the Progression and Treatment of Autosomal Dominant Polycystic Kidney Disease-The Promised Land?Medicina (Kaunas). 2023 May 10;59(5):915. doi: 10.3390/medicina59050915. Medicina (Kaunas). 2023. PMID: 37241147 Free PMC article. Review.
References
REFERENCES
-
- Heyer CM, Sundsbak JL, Abebe KZ, et al. Predicted mutation strength of nontruncating PKD1 mutations aids genotype-phenotype correlations in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2016;27(9):2872-2884.
-
- Rangan GK, Alexander SI, Campbell KL, et al. KHA-CARI guideline recommendations for the diagnosis and management of autosomal dominant polycystic kidney disease. Nephrology (Carlton). 2016;21(8):705-716.
-
- Halvorson CR, Bremmer MS, Jacobs SC. Polycystic kidney disease: inheritance, pathophysiology, prognosis, and treatment. Int J Nephrol Renov Dis. 2010;3:69-83.
-
- Luciano RL, Dahl NK. Extra-renal manifestations of autosomal dominant polycystic kidney disease (ADPKD): considerations for routine screening and management. Nephrol Dial Transplant. 2013;29(2):247-254.
-
- Lanktree MB, Guiard E, Li W, et al. Intrafamilial variability of ADPKD. Kidney Int Rep. 2019;4(7):995-1003.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous